Meta AnalysisID 6150
口服中成药治疗原发性骨质疏松的网状Meta分析
CRD42022325593
The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of oral Proprietary chinese medicines for primary osteoporosis。
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6150
- Evidence Id
- 14708
- Core Evidence Id
- 14708
- Source Meta Analysis Id
- 6129
- Herb2 Meta Analysis Id
- HBMA006129
- Crd Id
- CRD42022325593
- Title
- Network Meta-analysis of oral Chinese patent medicine in treatment of Primary osteoporosis
- Review Question
- The aim of this meta-analysis of randomized controlled trials is to evaluate the efficacy and safety of oral Proprietary chinese medicines for primary osteoporosis。
- Study Type Included
- Randomized controlled trials (RCTs) will be included
- Condition Being Studied
- Primary osteoporosis (POP) is a bone disease related to increasing age, it is estimated that in 2006, there were nearly 70 million OP patients in China, and the number of bone loss patients has exceeded 200 million. Despite the lack of recent epidemiological data, the number of OP and bone loss estimated in China has far exceeded the above figures. With the aging of the population, the harm of osteoporotic fractures is enormous, and it is one of the main causes of disability and death in elderly patients. Traditional Chinese medicine is based on the concept of kidney deficiency and has certain advantages in the treatment of OP, but at present, there are many types of proprietary Chinese medicines for the treatment of primary osteoporosis and the difference in efficacy is still inconclusive.
- Participant
- Inclusion criteria:The study participants met the international or domestic diagnostic criteria for primary osteoporosis, including outcomes for efficiency, bone density, and calcium concentration. Exclusion criteria: Studies without the above outcome measures, erroneous data or incomplete studies were excluded, and the most representative article was selected for repeated publications.
- Animal
- Human Disease Modelled
- Intervention
- Oral proprietary Chinese medicines are the main interventions (e.g., Zuo Gui Pill, You Gui Pill, Xian Ling Gu Bao Capsule, Qiang gu Capsule, gushukang Capsule, Gu Kang Granule and Jin Tiange Capsule)
- Comparator Control
- Oral conventional Western medicines (e.g., calcium, sodium alendronate, vitamin D, and its analogues)
- Main Outcome
- Main outcome measures included total efficiency, bone density, and calcium ion concentration Measures of effect All indicators were analyzed using a fixed-effects model. The ratio ratio (OR) is used if the index is a categorical variable, and a weighted mean genera difference (WMD) is used if it is a continuous variable.
- Outcome Measure
- Additional Outcome
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- China; Humans; Medicine, Chinese Traditional; Network Meta-Analysis; Nonprescription Drugs; Osteoporosis
- Contact
- Zhang Qing [email protected]
- Organisational Affiliation
- 湖北中医药大学 Hubei University of Chinese Medicine https://www.hbtcm.edu.cn
- Funding Source
- No source of funding
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2022-04-13
- Registration Date
- 2022-05-10
- Anticipated Start Date
- 2022-02-15
- Anticipated Completion Date
- 2022-06-15
- Title Cn
- 口服中成药治疗原发性骨质疏松的网状Meta分析
- Title En
- Network Meta-analysis of oral Chinese patent medicine in treatment of Primary osteoporosis
- Bilingual Status
- complete